SecBot SecBot
SECBOTREPLAY Home › Report › RYTM

RYTM · Rhythm Pharmaceuticals reported positive Phase 2 data for setmelanotide…

Rhythm Pharmaceuticals, Inc. · PRESS-RELEASE filed Jun 13, 2026 at 08:01 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 13, 2026 at 08:01 ET

Rhythm Pharmaceuticals reported positive Phase 2 data for setmelanotide in Prader-Willi syndrome at ENDO 2026, showing clinically meaningful BMI reductions, fat mass loss with lean mass preservation, and improvements in hyperphagia and anxiety. The results de-risk the path to Phase 3 development in a large unmet-need population, reinforcing the MC4R agonism thesis.

  • Phase 2 trial of setmelanotide in PWS (N=17) showed -3.06% mean BMI reduction at Month 6; 8 of 10 patients with moderate-to-severe hyperphagia achieved ≥7-point HQ-CT improvement.
  • DEXA scans (N=16) showed +0.74% mean lean mass gain and -4.19% mean fat mass loss; 6 of 9 adults had >5% fat mass reduction.
  • 10 of 15 patients with baseline PADQ >11 achieved ≥11-point improvement in anxiousness/distress behaviors.
  • Safety profile consistent with established setmelanotide data; no new safety signals.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access